Cargando…

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis

BACKGROUND & AIMS: Increased serum bile acids (BAs) have been observed in patients with non-alcoholic steatohepatitis (NASH). Pegbelfermin (PGBF), a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21), significantly decreased hepatic steatosis and impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yi, Decato, Benjamin E., Charles, Edgar D., Shevell, Diane E., McNaney, Colleen, Shipkova, Petia, Apfel, Abraham, Tirucherai, Giridhar S., Sanyal, Arun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689226/ https://www.ncbi.nlm.nih.gov/pubmed/34977519 http://dx.doi.org/10.1016/j.jhepr.2021.100392

Ejemplares similares

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
por: Charles, Edgar D., et al.
Publicado: (2018)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
por: Brown, Elizabeth A., et al.
Publicado: (2023)

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
por: Luo, Yi, et al.
Publicado: (2021)

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
por: Lawitz, Eric J., et al.
Publicado: (2021)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Opportunities for Smartphone Sensing in E-Health Research: A Narrative Review
por: Kulkarni, Pranav, et al.
Publicado: (2022)

Bile acids contribute to the development of non-alcoholic steatohepatitis in mice
por: Gillard, Justine, et al.
Publicado: (2021)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Understanding the Role of Healthy Eating and Fitness Mobile Apps in the Formation of Maladaptive Eating and Exercise Behaviors in Young People
por: Honary, Mahsa, et al.
Publicado: (2019)

A Web-Based Intervention for Relatives of People Experiencing Psychosis or Bipolar Disorder: Design Study Using a User-Centered Approach
por: Honary, Mahsa, et al.
Publicado: (2018)

Exploring Human-Data Interaction in Clinical Decision-making Using Scenarios: Co-design Study
por: Tendedez, Helena, et al.
Publicado: (2022)

Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance
por: Liu, Jinqi, et al.
Publicado: (2019)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Speech and Language Practitioners’ Experiences of Commercially Available Voice-Assisted Technology: Web-Based Survey Study
por: Kulkarni, Pranav, et al.
Publicado: (2022)

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Attitudes Toward the Use of Voice-Assisted Technologies Among People With Parkinson Disease: Findings From a Web-Based Survey
por: Duffy, Orla, et al.
Publicado: (2021)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
por: Connelly, Margery A., et al.
Publicado: (2020)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway
por: Filozof, Claudia, et al.
Publicado: (2015)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

The feasibility and acceptability of using a novel wrist worn cueing device to self-manage drooling problems in people with Parkinson’s disease: A pilot study
por: McNaney, Roisin, et al.
Publicado: (2019)

Detecting Mental Health Behaviors Using Mobile Interactions: Exploratory Study Focusing on Binge Eating
por: Vega, Julio, et al.
Publicado: (2022)

Who is your community? Co-designing a community engagement strategy for an emerging data platform.
por: Naude, Kim, et al.
Publicado: (2022)

A new preclinical model of western diet‐induced progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma
por: Green, Christopher D., et al.
Publicado: (2022)

Carvedilol impairs bile acid homeostasis in mice: implication for nonalcoholic steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2023)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice
por: Kasai, Kaichi, et al.
Publicado: (2023)

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
por: Dennis, Andrea, et al.
Publicado: (2021)

Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice
por: Yamada, Shoji, et al.
Publicado: (2018)

Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis
por: Lastuvkova, Hana, et al.
Publicado: (2021)

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism
por: Lu, Yifei, et al.
Publicado: (2022)

Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism
por: Lei, Yuanyuan, et al.
Publicado: (2022)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment
por: Morgan, Catherine, et al.
Publicado: (2020)

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
por: Qureshi, Irfan A., et al.
Publicado: (2018)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fq5282fgnckl0koulpv7ckvmbh